cyclophosphamide + doxorubicin + vincristine + prednisone + G-CSF + alemtuzumab

This is a multi-agent combination regimen consisting of six drugs: - Cyclophosphamide (an alkylating agent, small molecule chemotherapy) - Doxorubicin (an anthracycline antibiotic, small molecule chemotherapy) - Vincristine (a vinca alkaloid, small molecule chemotherapy) - Prednisone (a synthetic glucocorticoid corticosteroid, small molecule immunosuppressant/anti-inflammatory) - G-CSF (granulocyte colony-stimulating factor; a biologic cytokine that stimulates neutrophil production) - Alemtuzumab (a monoclonal antibody targeting CD52 on lymphocytes) The first four agents are the basis of the CHOP regimen, widely used in non-Hodgkin lymphoma and other hematologic malignancies. These drugs act by interfering with DNA synthesis or mitosis in rapidly dividing cells and by modulating immune responses[1][4][6]. G-CSF is added to reduce neutropenia risk by stimulating white blood cell recovery. Alemtuzumab targets CD52 on B and T lymphocytes for direct cytotoxicity via immune-mediated mechanisms. This specific combination is not standard but may be considered in research or high-risk/refractory settings where additional immunosuppression or cytotoxicity is desired.

Brand names

MabCampathCampath

Other names

CHOP-14 + alemtuzumabAlemtuzumab-CHOPA-CHOPCampath-CHOP